Connect
← Return to New Pancreatic Cancer Diagnosis
Discussion
New Pancreatic Cancer Diagnosis
Pancreatic Cancer | Last Active: 5 hours ago | Replies (34)Comment receiving replies
A PHASE II STUDY OF PACLITAXEL PROTEIN BOUND + GEMCITABINE + CISPLATIN+
PARICALCITOL AS PREOPERATIVE TREATMENT IN PATIENTS WITH UNTREATED RESECTABLE, BORDERLINE RESECTABLE AND LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS
NABPLAGEM-NEO 2017-001
HonorHealth IRB# 1060386
HonorHealth Research Institute
I was diagnosed at Mayo on November 26 2018 and went on this study combination of FDA approved drugs. The combination was not approved at the time. I did 18 weeks of chemo 2 weeks on and 1 week off. After 6 weeks I did 33 days of radiation. Today I have no activity that can be detected even though I still have a mass of 2.3 cm. My CA19-9 at last tested in May was 13.4 I take Xeloda 5 days a week.
Replies to "A PHASE II STUDY OF PACLITAXEL PROTEIN BOUND + GEMCITABINE + CISPLATIN+ PARICALCITOL AS PREOPERATIVE TREATMENT..."
Connect
Thank you so much @mcharlesfrancis for sharing that regimen with us! A couple of comments or questions since it's our mutations that drive treatment types. 1. Did you have any metastasis in liver or anywhere else when you began treatment? 2. You didn't have surgery after diagnosis? 3. You don't cite any mutations (previous posts), other than the fact you do not have BRCA or TP53 genes? This is critical, as paclitaxel is not or not always effective for the TP53 gene which is quite common in cancer. I do have the TP53 gene, though my blood biopsy in January said the significance of its base substitution was PROBABLY benign. Since I now have cancer blooming like spring flowers in me, I doubt that it was benign. This is a good regimen for those without TP53; at least I can say that. Thank you so much for sharing.